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The Chernobyl accident in 1986 exposed thousands of people to various 
radioactive isotopes of iodine, particularly iodine-131 (I-131). In subsequent years after 
exposure, a large increase in thyroid cancer among those exposed as children and 
adolescents was found, particularly in Belarus, Russia, and Ukraine. Since the natural 
history of thyroid nodules is not clear, we examined the relationship between the 
presence of thyroid nodules 12-14 years after the accident and measurement-based 
individual I-131 thyroid dose estimates. The cohort consisted of 13,008 individuals who 
were under the age of 18 years on April 26, 1986 and who resided in contaminated areas 
of Ukraine and had an examination between April 1998 and December 2000. Individual 
estimates of radiation dose to the thyroid were calculated based on radioactivity 
measurements made shortly after the accident, environmental transport models, and 
interview data. Excess odds ratios (EORs) were estimated using logistic regression 
models. At least one pathologically confirmed thyroid nodule was observed in 263 
individuals (2.02% of the cohort). There was a linear-exponential relationship between I-
131 exposure and thyroid nodule risk in an EOR model (p-value: 0.00460) with the EOR 
increasing at lower doses before plateauing and declining at higher doses. The linear 
EOR over the whole dose range was 0.89 (95% CI: 0.42, 1.64) for prevalence of all 
nodules and 0.41 (95% CI: 0.09, 0.95) for prevalence of non-neoplastic nodules 
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(excluding thyroid cancer and follicular adenoma). The EORs under 5 Gy for prevalence 
of all nodules and prevalence of non-neoplastic nodules were 1.08 (95% CI: 0.53, 1.95) 
and 0.57 (95% CI: 0.17, 1.22), respectively. The EOR per Gy varied significantly by 
oblast of residence but not by sex, age, iodine status, or thyroid volume. Exposure to 
radioactive iodine was strongly associated with an increased risk of thyroid nodules 
among those exposed at ages less than 18 years. Thyroid nodule risk showed a nonlinear 
relationship with dose received but overall was lower than thyroid cancer risk in previous 
studies of the same cohort. This suggests that I-131 exposure may be more effective in 
inducing thyroid cancer or follicular adenoma than non-neoplastic thyroid nodules. 
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Epidemiology and Biological Development of Thyroid Cancer 
 
Although thyroid cancer makes up a relatively small proportion of cancer overall, 
the incidence of thyroid cancer has been increasing over approximately the past 30 years 
worldwide while the thyroid cancer mortality rate remains relatively constant (see Figure 
1).1,41 The American Cancer Society predicts that there will be approximately 62,450 new 
cases of thyroid cancer and 1,950 thyroid cancer-related death in the U.S. in 2015.18 
Thyroid cancers account for approximately 90% of malignancies of the endocrine 
system.20 The increase in thyroid cancer stands in contrast to the decreasing incidence of 
many head and neck cancers in the U.S.8 Reasons for increases in the rates of thyroid 
cancer continue to be debated but may include improved diagnosis and surveillance 
(including detection of small thyroid nodules due to increased use of sensitive imaging 
techniques such as ultrasound), exposure to radioactive fallout, and medical diagnostic 
tests and radiotherapy treatments.1 
Figure 1: Age-adjusted incidence and mortality rate for thyroid cancer in the United 
States from 1975 – 2011. This figure was originally published by the National Cancer 
Institute’s Surveillance, Epidemiology, and End Results Program.  
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Thyroid tumors are classified by the cell type from which they develop.23 A 
thyroid tumor can include a wide variety of thyroid lesions such as well-differentiated 
benign neoplasms and goiter nodules, well-differentiated follicular cancers, poorly 
differentiated and de-differentiated cancers, and medullary and anaplastic carcinomas.20 
Medullary thyroid cancers develop from parafollicular thyroid cells (C-cells) that produce 
calcitonin, a circulating hormone, and account for the remaining 5% of all thyroid 
malignancies.23 Approximately 25% of medullary thyroid cancers are familial.23 Most 
thyroid carcinomas are nonmedullary and arise from thyroid epithelial cells.23 These 
represent approximately 95% of thyroid carcinomas and are divided into four histologic 
subtypes: papillary (85%), follicular (11%), Hürthle cell (3%), and anaplastic (1%).23 Of 
these, an estimated 95% are sporadic carcinomas, and the remaining cancers are thought 
to have a hereditary origin.23  
The increase in thyroid cancer in the U.S. is due in large part to an increase in 
papillary thyroid cancer (PTC) incidence, whereas the rates of follicular, anaplastic, and 
medullary thyroid cancer have not changed noticeably.78 PTCs are further classified into 
histological variants based on architectural and cytoplasmic features that may be 
associated with invasive tumor properties and prognoses.20 Follicular thyroid cancer is 
more likely to present as a solitary nodule with irregular borders and tends to have a 
greater degrees of recurrence.20 Over 90% of follicular tumor variants are well-
differentiated and most retain the biological properties of normal follicular cells.20 
However, the distinction between PTC and follicular carcinoma is not always clear since 
PTC can show both papillary and follicular cellular architecture.99 Indeed, multiple 
nuclear attributes are necessary for PTC diagnosis, and PTC may be misdiagnosed as 
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either follicular carcinoma or follicular adenoma in some cases.99 Follicular adenomas are 
also benign tumors, but they can be precursors for some follicular carcinomas.79 They are 
thought to be monoclonal tumors arising spontaneously from follicular epithelium.67 The 
risk that a follicular adenoma will undergo malignant degeneration is unknown, but some 
highly cellular forms of atypical adenomas may develop into cancers.67  
While the survival rates for early stage papillary and follicular carcinoma are 
typically quite high, anaplastic (or un-differentiated) carcinomas are particularly 
aggressive, have a high mortality rate, and do not respond to radioiodine therapy.20 Many 
less-differentiated thyroid cancers arise after undergoing a process of stepwise de-
differentiation of papillary or follicular carcinomas.79 Anaplastic carcinomas are among 
the least common thyroid malignancies.99 Overall, thyroid cancer is the most common 
pediatric endocrine cancer, and PTC is its most frequent histological type (up to 72%).71 
Follicular adenoma is the most frequent nonmalignant diagnosis of thyroid disease in 
children with thyroid nodules.71 Approximately 75% of pediatric patients with both 
benign and malignant thyroid nodules are clinically asymptomatic.71 Incidence rates of 
thyroid cancer increase with age and at younger ages (< 50 years) are three to four times 
higher in females as in males.2  
Ultrasound is an important method in the diagnosis of thyroid disease.71 It is a 
relatively sensitive but not especially specific tool for thyroid cancer diagnoses.102 The 
use of ultrasound may increase the number of detected thyroid nodules up to 10 times 
relative to clinical palpation.23 Ultrasound guided fine needle aspiration biopsy (FNAB) 
and cytologic examination of collected cells are widely used to increase sensitivity and 
specificity of diagnostic testing for thyroid cancer.79 Although FNAB can often improve 
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diagnoses of malignant or benign nodules, a conclusive diagnosis cannot be obtained for 
about a fourth of all nodules, making clinical management of such nodules challenging.79 
Radiation-Induced Thyroid Cancer 
Exposure to ionizing radiation during childhood is one of the strongest known risk 
factors for thyroid cancer. A pooled analysis of five large cohort studies of individuals 
exposed to medical radiation or atomic bomb radiation under 20 years of age found that 
the estimated excess relative risk (ERR) at 1 gray (Gy) was 7.7, one of the highest 
radiation risks for any solid cancer.12 The pooled analysis, including a cohort of infants 
irradiated to treat an enlarged thymus and atomic bomb survivors with a long follow-up 
(up to 60 years), suggested that radiation risk peaks at about 15-19 years after exposure 
before declining but not disappearing.12,57,58 Medical exposures to radiation appear to 
increase the risk of thyroid cancer at relatively low doses.1 However, increased risks of 
thyroid cancer have also been observed from 5 to more than 40 years after high doses 
radiotherapy for childhood cancer and following treatment with radioactive iodine.1,12,60 
Even though there is a strong association between exposure to ionizing radiation and 
thyroid cancer, only about 9% of thyroid cancers in the general population are attributed 
to radiation.3 Nevertheless, increasing pediatric thyroid exposures over time due to 
medical irradiation from dental X-rays, interventional radiology, diagnostic computed 
tomography, and nuclear radiotherapy for hyperthyroidism and thyroid cancer may be 
contributing to the increasing rates of thyroid cancer.1 
There is compelling evidence that the younger a person is at the time of radiation 
exposure, the greater the risk of developing radiation-induced thyroid cancer at some 
point in the future.7 In other words, this suggests that the thyroid is more sensitive to 
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radiation in children and adolescents than in adults. Indeed, studies of atomic bomb 
survivors and a pooled analysis of irradiated populations showed that external radiation 
exposures at young ages (0-4 years) result in the greatest risk of thyroid cancer.25,26,27,28 
Furthermore, studies of thyroid cancer in adults after medical exposure to iodine-131 (I-
131) have less consistently shown thyroid cancer risks than studies in children and 
adolescents.61,64,74 While the underlying biological mechanisms of these differences 
remain unknown, age-related variations in thyroid metabolism are likely to be important 
contributors.63  
One potential mechanism through which ionizing radiation could induce 
carcinogenesis involves molecular lesions that can cause structural DNA damage, 
including double strand breaks that affect the ability of the cell to transcribe genes 
encoded by the altered DNA.2,96 Lesions can also produce mutations in the cell's genome, 
which may alter the survival ability of daughter cells.96 Cellular repair mechanisms may 
not be equally capable at low and high doses of ionizing radiation.2,96 Cells of different 
tissue types also vary in their radio-sensitivity and ability to repair radiation-induced 
damage.2,95 There is some evidence that delivering radiation in fractions may allow 
enough time for cellular repair in noncancerous cells and may lower risk of DNA damage 
compared with a single acute dose.2,12,97 However, it has also been shown that 
fractionated low dose radiation can result in the accumulation of DNA damage over 
time.95 The precise mechanisms involved in the repair of particular types of DNA damage 
or mutations remain unidentified.2,95 The effect of dose fractionation in humans is 
difficult to assess since variation in dose rates within individual studies is relatively 
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small.2 Therefore, it is important to study populations receiving different types of 
radiation exposure over various time periods. 
Because the type of radiation exposure and other factors, such as age at exposure 
or genetic susceptibility, can vary between populations, it is often challenging to compare 
risks derived from different populations. Depending on the circumstances of exposure, 
including the source of radiation and the decay rate of particular radioactive elements, 
doses can be received over different time periods. For example, individuals may receive 
chronic exposures over many years (as occurred at the Hanford nuclear site) or more 
acute exposures over a fraction of a second (as occurred with atomic bomb survivors). 
The age and temporal patterns of radiation risk from chronic, protracted doses of 
radiation may be different from those due to acute doses of radiation. Additionally, the 
populations under study often have different characteristics, such as age at exposure or 
iodine sufficiency, that might alter susceptibility to the development of cancers like 
thyroid carcinoma and therefore affect the observed radiation risk. 
Iodine-131 Exposure After the Chernobyl Accident 
One important non-medical scenario of thyroid irradiation in humans is internal 
exposure to radioactive iodines – particularly I-131 – from nuclear weapons production 
(the Hanford nuclear site and Mayak nuclear facility), testing (Nevada, Kazakhstan, and 
the Marshall Islands), or nuclear reactor accidents (Chernobyl and the Fukushima Daiichi 
nuclear power plants). After release into the atmosphere, I-131 can be transported long 
distances before being deposited onto soil or organic matter.103 People (or animals, such 
as cattle) can ingest substances that have been contaminated with radioactive iodine. 
Iodine is required by the thyroid to produce hormones, such as triiodothyronine and 
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thyroxine, that regulate metabolism.104 After iodine uptake by tissues (particularly thyroid 
tissue), much of the remaining ingested iodine is usually excreted from the body.104 Since 
iodine is typically retained readily in the thyroid (depending on thyroid metabolic rate 
and previous iodine concentration in the thyroid), the thyroid often receives 
comparatively higher doses from internal ingestion of I-131 relative to other tissues in the 
body.104 However, other body tissues can still be exposed to beta and gamma radiation 
from the decay of I-131.104 Although I-131’s biological half-life of approximately 100 
days after accumulation in the thyroid is longer than its physical half-life of 8.04 days, I-
131 released in the environment largely decays away within approximately two months.  
While there is abundant evidence relating thyroid cancer risk to gamma and X-
rays in children, the evidence from exposure to radioactive iodines is more limited.13 The 
dose-response relationship involving internal radiation exposure to I-131 has been more 
difficult to study compared with external exposure due to challenges in dose 
reconstruction and large uncertainties in dose estimates.35,36 Most studies of 
environmentally exposed populations have to rely on retrospective dose reconstruction 
and use of self-reported residential and dietary information many years after the 
exposures occurred.35,36 Following the Chernobyl nuclear plant accident on April 26, 
1986, tens of thousands of thyroid radioactivity measurements were taken on residents of 
most contaminated territories in Ukraine, Belarus, and the Russian Federation, facilitating 
reconstruction of I-131 thyroid doses.     
 An increase in thyroid cancer incidence near the Chernobyl nuclear plant site was 
observed beginning approximately 4 years after the accident and slowed around 2005.13 
There was no evidence that the incidence increased for those who were born after 1986 
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and were therefore not exposed to I-131.10,11 The short latency period following I-131 
exposure was unexpected since it was generally longer (greater than 10 years) in studies 
of externally irradiated populations.17,59 Several analytic epidemiological studies (both 
case-control and cohort studies) conducted in 1990s in Ukraine, Belarus, and the Russian 
Federation have convincingly linked internal exposure to I-131 during childhood to a 
large increase in thyroid cancer incidence following the Chernobyl accident in those 
countries.4,5,6 For example, in a cohort of Ukrainian individuals exposed to I-131 under 
the age of 18 and screened according to a standardized protocol and irrespective of dose, 
an approximately linear dose-response was found with an excess relative risk per gray 
(ERR/Gy) for prevalent thyroid cancer of 5.25.5 It was estimated that 75% of prevalent 
thyroid cancer cases in this cohort could have been avoided in the absence of radiation 
exposure.5 A later study of thyroid cancer incidence in the same cohort found a lower but 
significant ERR/Gy of 1.91 persisting for 20 years after exposure.4 This study is distinct 
in that it used direct measurements of thyroid radioactivity taken within two weeks of the 
accident, personal interview data, and ecological transport models to calculate individual 
I-131 thyroid doses more accurately.5 Based on post-Chernobyl studies of thyroid cancer, 
the magnitude of risk from exposure to internal I-131 radiation appears to be slightly 
lower than but compatible with risk from external radiation exposure in childhood.4,9 
Multiple factors may act as confounders or effect modifiers of the relationship 
between thyroid cancer and I-131 dose. Interactions between sex and dose and between 
age and dose have been found in previous studies, with females having a slightly larger 
ERR/Gy than males and those exposed at younger ages having larger ERRs/Gy than 
those exposed at older ages.4,7,12,42,53,58,91 Consistent with the age at exposure effect on 
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radiation risk, Belarus, Ukraine, and four regions in Russia saw the highest increases in 
thyroid cancer incidence among those exposed to the Chernobyl fallout as children or 
adolescents.10 In addition, iodine deficiency endemic to regions surrounding the 
Chernobyl power plant and intake of stable iodine (iodine prophylaxis) following the 
accident emerged as possible modifiers of I-131 thyroid cancer risk in some 
studies.2,43,44,45,86 A higher thyroid cancer risk was also found in those with simple diffuse 
goiter, a marker of past iodine deficiency, in Ukraine and Belarus.5,6 However, not all 
research has found iodine deficiency to be a significant modifier of I-131 risk.4,46,47 The 
modifying role of iodine deficiency is challenging to study because measures of stable 
iodine intake at an individual level during the most relevant time period, the time at 
exposure, are rarely available in retrospective epidemiological studies. One potential 
mechanism by which iodine deficiency might increase risk of radiation-related thyroid 
cancer is through increased stimulation of thyroid cell proliferation resulting from 
reduced production of thyroid hormone and a subsequent increase in production of 
thyroid stimulating hormone (TSH).44 
Biomarkers for Thyroid Cancer 
Serum based biomarkers such as calcitonin and thyroglobulin have been 
historically important in evaluating thyroid cancer but lack sufficient specificity.70 Assays 
to detect TSH or thyroid antibodies can also be used to identify thyroid dysfunction and 
improve the sensitivity and accuracy of FNAB.23 Immunohistochemical biomarkers for 
the recognition of specific proteins might be valuable, especially when FNAB 
interpretation is difficult due to atypical cellular patterns or the absence of vascular and 
capsular invasions.20 Unfortunately, widely studied immunohistochemical biomarkers 
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such as the monoclonal antibody HBME-1, the cytokeratin CK19, the lectin galectin-3, 
and the tyrosine kinase receptor c-met have not shown an adequate sensitivity and 
specificity for use in diagnostic procedures.20 Indeed, it has been challenging to find 
individual distinguishing histological features that are specific for each type of thyroid 
cancer.23 However, the search for more accurate thyroid cancer biomarkers continues.  
Somatic genetic alterations in particular may prove more accurate and useful than 
serum biomarkers.70 Thyroid cancer can be initiated through the accumulation of genetic 
and epigenetic alterations such as activating or inactivating somatic mutations, altering 
gene expression patterns, microRNA dysregulation, or abnormal gene methylation.79 
Finding relevant somatic alterations is challenging since the progression from a normal 
cell to a tumor is complex and may require multiple genetic and epigenetic events.70 
Indeed, multiple mutations are likely responsible for most thyroid cancers.70 Although 
mutations have been found in non-medullary thyroid cancers, no single mutation or 
rearrangement has been useful in evaluating all thyroid malignancies.8  
One process of interest in the formation of thyroid cancer is disruption of the RET 
proto-oncogene on chromosome 10, which is associated with medullary thyroid cancers.8 
RET rearrangements also occur in about 20% - 40% of PTCs and are especially common 
in tumors that developed after the Chernobyl accident.18 RET/PTC1 and RET/PTC3 are 
specific types of rearrangements involving intrachromosomal inversions and are 
particularly common variants.79 Gain-of-function in the RET gene can occur when it is 
rearranged and joined to a new promoter from a gene that is expressed in thyroid 
follicular cells, which leads to uncontrolled downstream signaling.70 Multiple separate 
genes are known to rearrange with the RET gene, causing mutations that affect PTC 
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risk.70 Point mutations can also occur in the RET gene that affect the risk of medullary 
thyroid cancer due to a gain-of-function in the RET receptor.70 RET point mutations are 
currently among the most sensitive and specific biomarkers for diagnosing medullary 
thyroid cancer.70 However, since RET mutations are found in both benign thyroid 
adenomas and in thyroid cancer, they do not appear to be exceptionally useful for 
evaluating thyroid cancer.8  
BRAF mutations occur more frequently in sporadic PTCs than do RET 
mutations.70 BRAF point mutations appear to result in a high rate of malignant 
transformations and, according to some studies, in particularly aggressive PTCs in certain 
cases.70 BRAFV600E, an amino acid substitution (valine to glutamate) at a particular 
location on the BRAF gene, is found in about 45% of PTCs, 20% - 40% of poorly 
differentiated thyroid carcinomas, and 30% - 40% of anaplastic thyroid carcinomas. 
BRAF mutations are almost never found in follicular carcinomas or in benign lesions and 
therefore may be a specific marker for PTC.71 However, while the specificity of BRAF 
mutations is usually high, the sensitivity for PTC diagnosis is often rather low (< 35%).80 
This is because BRAF mutations occur infrequently in PTCs that have follicular, 
trabecular, or solid growth patterns.80 They also may be more likely to result from 
chemical exposures in the diet, such as iodine intake, or from the environment.79 
BRAFV600E mutations are far more common in adults than in children.71 RET/PTC 
rearrangements, on the other hand, are found in no more than 20% of sporadic PTC in 
adults but may be far more prevalent in children (40% - 70%).71  
Other mutations may also play a role in the development of thyroid cancer, but 
they require further study. For instance, a tyrosine kinase gene, NTRK1, has also shown 
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rearrangements, but it has not been particularly useful for predicting prognoses or for 
differentiating benign from malignant thyroid disease.8 In addition, mutations in the RAS 
gene appear to increase the risk of uncontrolled proliferation, which can predispose the 
cell to accumulation of other genetic defects and eventual tumor formation.70 Among 
papillary carcinomas, nearly all tumors with a RAS mutation form neoplastic follicles but 
no papillary structures.79 They are therefore diagnosed as a follicular variant of papillary 
carcinoma.79 RAS mutations appear to occur at similar rates in benign follicular adenomas 
(20% - 40%) and in follicular carcinomas (24% - 44%).79 Since they occur in both benign 
adenomas and in follicular carcinomas, follicular adenomas with RAS mutations may be 
precursors for RAS positive follicular carcinomas and the follicular variant of papillary 
carcinomas.79 Because BRAF and RAS mutations are often found in well-differentiated, 
poorly differentiated, and anaplastic thyroid cancers, they may be early events in thyroid 
cancer development.79 The progression of cancer may involve additional later mutations 
in other genes, such as TP53 or CTNNB1.79 Other potential alterations currently being 
studied include abnormal translocations of the PAX8 transcription factor with the PPARγ 
gene and mutations in the P53 tumor suppressor gene.70  
Somatic mutations found in thyroid cancers are often mutually exclusive and 
involve genes that activate the mitogen activated protein kinase (MAPK) signaling 
cascade (BRAF, RAS, and RET/PTC).79 Since alterations in these genes can be detected in 
over 70% of PTCs, activation of the MAPK signaling pathway is likely to be a major 
early event in the development of PTC.70,76 An estimated 70% - 80% of thyroid cancers 
should have at least one of the known mutations, so DNA mutation panels could improve 
diagnostic accuracy of thyroid tumor FNAB.70 Nevertheless, limitations persist since up 
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to 30% of thyroid cancers have no currently known mutations.70 Epigenetic studies of 
DNA methylation, histone modification, and microRNA silencing may provide useful 
diagnostic information as well.70 These mechanisms regulate DNA by silencing the 
expression of genes when they are activated.70 Defects in epigenetic mechanisms can lead 
to atypical gene expression.70 Epigenetic events can also alter the function of tumor 
suppression genes that lead to the activation of important signaling pathways.79 However, 
specific methylator phenotype signatures have not yet been identified and miRNA 
signatures have only been established in small, prospective trials, so larger clinical trials 
and further research are needed for the use of epigenetic clinical biomarkers for 
diagnostic purposes.70 Furthermore, studies of high-throughput gene expression profiles 
have not been standardized, so findings from such studies may not always be consistent.70 
Proteomic and immunohistochemical studies have also shown promising initial results, 
but prospective studies are required to demonstrate their clinical usefullness.70 In 
summary, many thyroid tissue biomarkers have been identified but few are being used in 
routine clinical practice since the development of tumors is not fully understood and 
further research and validation is needed.8,70 
Biomarkers in Radiation Exposed Populations 
Studies of populations exposed to radiation may improve comprehension of the 
biological mechanisms related to the development of thyroid cancer because of the strong 
and consistent association between radiation exposure and risk of thyroid cancer. Based 
on past studies, the latent period from radiation exposure to clinically diagnosed thyroid 
neoplasms has varied broadly from 4 years to the maximum length of follow-up for a 
cohort, 60 years.66 PTC is the primary type of thyroid cancer associated with radiation 
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exposure.81 It is also the type of thyroid cancer that occurred most often in residents of 
the area around Chernobyl exposed during childhood.81  
A high frequency of chromosomal rearrangements such as RET/PTC has been 
found in post-Chernobyl thyroid tumors, while the frequency of BRAF and RAS point 
mutations was lower than typically observed in sporadic tumors in the general 
population.81 RET/PTC rearrangements were also found in 52.4% of post-Chernobyl 
benign nodules, in 37.5% of benign nodules exposed to external radiation, and in 13.9% 
of naturally occurring nodules in one study.77 Another study found a high prevalence of 
RET gene rearrangements (62.3%) in PTCs in the first 10 years after the Chernobyl 
accident, while NTRK1 rearrangements were less common (3.3%).23 A more recent 
cohort study found the novel ETV6/NTRK3 chromosomal rearrangement to be a common 
genetic event in thyroid cancers in individuals exposed to radiation after the Chernobyl 
accident but not in those with sporadic thyroid cancer.75 
In contrast to patients with RET/PTC rearrangements, those with tumors having 
BRAF and RAS point mutations received lower average I-131 doses, were older at the 
time of the accident, and were more likely to be female.81 PAX8/PPARγ rearrangements, 
which occur more often in follicular thyroid carcinoma, were also identified after the 
Chernobyl accident.81In atomic bomb survivors, RET/PTC rearrangements showed 
significantly increased frequency with increasing dose.76 BRAFV600E point mutations, on 
the other hand, were less frequent in cases exposed to higher radiation doses.76 Those 
with PTC having RET/PTC rearrangements also developed cancer earlier than did cases 
with BRAFV600E point mutations.76 Chromosomal rearrangements are therefore likely to 
be an important contributor in radiation-induced thyroid cancer.76 The connection 
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between chromosomal rearrangements and ionizing radiation exposure has been 
corroborated by studies in human thyroid cell lines and tissue xenografts in mice.82,83 
Although important preliminary information has been gathered on the relationship 
between certain somatic alterations and radiation dose, further follow-up of the existing 
cohorts, as well as large scale tissue-based studies, are necessary to improve 
understanding of the role of specific genes and pathways in radiation-related thyroid 
carcinogenesis. 
Histology of Thyroid Nodules 
The term thyroid nodule is comprehensive and can include both neoplasms 
(adenomas and carcinomas) and non-neoplastic nodules.24 An adenoma is a specific type 
of benign tissue growth having a capsule and a gland-like cellular structure that can be 
classified by the size or presence of follicles.99 The presence of metastasis or capsular or 
vascular invasion is typically the most clear differentiator between follicular carcinoma 
and follicular adenoma since most histological characteristics remain similar.99 In 
contrast, a nodule could also be a cyst, lobule, carcinoma, or other focal lesion that differs 
from the typical thyroid tissue.99 Nodules can be further characterized based on the 
accumulation of thyroid gland secretions (colloid nodules), irregular growth of thyroid 
cells (hyperplastic nodules), or filling of thyroid cells with fluid (cystic nodules).99 
Colloid nodules are typically the most likely to be multinodular and hypofunctioning, and 
colloid adenomas often appear similar to normal thyroid tissue.67 Non-neoplastic nodules 
can include inflammatory lesions and hyperplasia, while neoplastic nodules may include 
follicular epithelial neoplasms such as follicular adenoma or differentiated papillary or 
follicular carcinomas.99 In contrast to hyperplastic nodules, neoplasias tend to have a 
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surrounding capsule, have a relatively uniform cellular architecture that differs from 
surrounding tissue, and reproduce in an uncontrolled manner.99 
Studies have found that thyroid nodules removed surgically were an estimated 
42% - 77% non-neoplastic colloid nodules, 15% - 40% adenomas, and 8% - 17% 
carcinomas.67 The characterization of thyroid cells often relies on variations in 
distinguishing nuclear features, which are in turn expected to affect cell behavior.99 Based 
on uptake of radioactive iodine, thyroid nodules can be classified as hyperfunctioning 
(hot), hypofunctioning (cold), or normal (warm) depending on the amount of thyroid 
hormone produced.23 Hot nodules have a prevalence of about 5% and are malignant in 
about 5% of cases.23 An estimated 80% - 85% of nodules are cold, with 10% - 15% 
proving to be malignant.23 The remaining 10% - 15% of nodules are warm, of which 
about 9% are malignant.23 Solid nodules are also more likely to be malignant, but most 
solid lesions are benign.71  
Thyroid nodules develop relatively frequently in the U.S., with an estimated 
lifetime incidence of up to 50%.8 Thyroid nodules are found in about 1.5% of men and 
6.4% of women, and their frequency dramatically increases with age.8 The observed rates 
of thyroid nodules also strongly depend on detection methods and diagnostic criteria 
involved.9 Previous studies have found a thyroid nodule prevalence of 2% - 6% using 
palpation, 19% - 35% with ultrasound, and up to 65% via autopsy.22 Although the 
prevalence of nodules is larger in autopsy studies, many nodules found at autopsy may be 
small, non-palpable, and not clinically important.8 It has been reported that in children, 
between 9.2% and 50% of thyroid nodules are likely to be malignant, while the incidence 
of thyroid nodule malignancy in adults is between 5% and 15%.71 Up to 35% of thyroid 
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glands that are removed have small (< 10 mm) PTCs that are considered clinically 
inconsequential.67 The majority of malignant nodules are found in patients having a 
solitary nodule on physical examination rather than multiple nodules, although it may be 
discovered that multiple nodules are actually present after imaging.67 It remains unclear 
whether solitary nodules are significantly more likely to be malignant.71 While it is 
challenging to histologically or morphologically differentiate monoclonal from 
polyclonal nodules, it may be important since adenomas can progress in an area 
undergoing hyperplastic development.99  
Thyroid nodule size may also affect the risk of malignancy, although this 
evidence has been inconsistent.8,40,74 Because previous guidelines recommended biopsy 
on nodules > 10 mm, small carcinomas may have been missed.23 However, when 
combined with other characteristics detected using ultrasound, size may be a useful 
characteristic for diagnosis.72  Most thyroid nodules change little over the short term, but 
they can enlarge, shrink, or disappear.67 Up to 38% of nodules previously detected by 
palpation disappear altogether.23 Other research found that nodule size decreased about 
13% of the time, disappeared 22%, did not change 46%, and enlarged 19%.68 The 
behavior of a nodule often depends on its histologic features, the patient’s age, the tumor 
stage at diagnosis, and initial treatment.67  
Significant growth in a nodule is considered a risk factor for malignancy. 
Discussion over the precise classification of significant growth is ongoing, but one 
proposed definition is a 20% increase in nodule diameter with a minimum increase in two 
or more dimensions of ≥ 2 mm over a 5 year period.23 Thyroxine treatment is sometimes 
recommended for those with benign thyroid nodules in order to reduce the size of the 
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nodule or prevent further growth.69 In addition, family history is considered a risk factor 
for thyroid cancer, which is suggestive of a genetic predisposition.67 About 41% of 
children with thyroid nodules have a family history of some type of thyroid disorder.71  
Relationship Between Thyroid Nodules and Thyroid Cancer 
Even though incidence rates of thyroid cancer in the general population have been 
increasing and are higher in irradiated populations, thyroid cancer can be challenging to 
study due to its relative rarity. For instance, the overall age-standardized estimates of 
incidence rates for thyroid cancer worldwide in 2008 were 4.7 per 100,000 women and 
1.5 per 100,000 men.1 Adolescents have lower incidence rates, with a study of European 
children from 1988-1997 finding age-standardized incidence ranging from 0.5 to 1.2 per 
million for children 0 to 14 years old and from 4.4 to 11.0 per million for children 15-19 
years old.19 While thyroid cancers are relatively rare, representing 1% of all cancers and 
0.5% of all cancer deaths, thyroid cancer occurs in about 5% of all thyroid nodules 
independent of their size.23 Despite the widespread occurrence of thyroid nodules, most 
are asymptomatic.23 Still, there appears to be a strong relationship between a history of 
benign thyroid nodules and thyroid cancer with an estimated odds ratio of approximately 
10.29,30,31 Since thyroid nodules are believed to be an early marker of thyroid cancer and 
are more common than thyroid cancer, studies of nodules may provide useful information 
regarding cancer risks.21,29,30,31 
Several studies have suggested that the incidence of thyroid nodules might 
increase after exposure to radiation, with those exposed at younger ages and females 
likely being at a greater risk.2 In the atomic bomb survivors cohort, a significant linear 
dose-response relationship of comparable magnitude was found for malignant and benign 
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thyroid nodules.31 In addition, increased risk of both benign and malignant thyroid 
nodules was reported after high dose external radiotherapy.33,34Although post-Chernobyl 
studies of thyroid cancer suggest that exposure to I-131 has about the same risk for 
thyroid cancer as acute, external exposures do, the United Nations Scientific Committee 
on the Effects of Atomic Radiation noted that the relationship between I-131 exposure 
and the development of benign thyroid nodules is not well-characterized and risk 
estimates vary widely.2  
When comparing findings for benign thyroid nodules across different studies it is 
important to keep in mind that their rates have a strong dependence on detection methods 
and diagnostic criteria used.9 Because it is difficult to differentiate benign nodules and 
benign neoplasms based on FNAB, studies often combine them as one outcome.24 In 
addition, previous studies that explored risk of thyroid nodule prevalence after internal I-
131 exposure were limited in size and had little information on individual doses or had 
does estimates associated with large uncertainties.35,36 A study of those exposed to 
radioactive fallout in Kazakhstan found a significant positive relationship between 
internal radiation exposure, which was mainly from I-131, and the prevalence of thyroid 
nodules.30 Internal exposure to iodine radionuclides was estimated to be about 1/4 to 
1/3 as 
effective as exposure to external radiation at inducing thyroid nodules.30 More recent 
research using Bayesian methods to take uncertainties in thyroid I-131 dose estimation 
into account found that the biological effectiveness for thyroid nodule induction was 
similar for internal and external dose in the Kazakhstan cohort.84 Studies involving the 
inhabitants of the Marshall Islands exposed to radiation from nuclear weapons testing 
found a significant inverse association between distance from the explosion and thyroid 
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nodule prevalence.37 However, individuals exposed to radioactive fallout that included I-
131, including residents of Kazakhstan, Nevada, and the Marshall Islands, were also 
exposed to substantial levels of external gamma radiation.2,38 
Data concerning the precise dose-response relationship for thyroid nodules and its 
potential modification by risk factors such as sex and age at exposure remain limited. 
Insights into the dose-response relationship for thyroid nodules are valuable since 
exposure to an internal radiation emitter such as I-131 can occur in environmental, 
occupational, and medical settings, and the biological development of thyroid nodules 
and thyroid cancer after radiation exposure is not well understood. Furthermore, data on 
I-131 risk after the Chernobyl accident may be important in anticipating the 
consequences of the Fukushima Daiichi nuclear power plant accident as well as of other 















MATERIALS AND METHODS 
Thyroid Screening and Data Collection Procedures 
Details of the study methods have been published previously.13 Briefly, the 
Ukrainian-American cohort (n=13,243) was assembled in order to evaluate the 
relationship between radiation dose received by the thyroid from I-131 and the risk of 
thyroid cancer and other thyroid diseases (hyperthyroidism, hypothyroidism, and thyroid 
nodules) based on standardized thyroid screening examinations.13 Individual thyroid 
doses were estimated for the entire cohort from direct thyroid radioactivity measurements 
performed within two weeks of the accident.5,13 All cohort participants were born 
between April 26, 1968 and April 26, 1986, making them 18 years old or younger at the 
time of the accident.13 Assessment of thyroid nodule prevalence was performed from 
April 1998 through December 2000.13 The study was reviewed and approved by the 
institutional review boards of the participating organizations in Ukraine and the United 
States, and all participants or their legal guardians signed an informed consent form. The 
screening procedure consisted of ultrasonography and palpation by an ultrasonographer 
and independent clinical examination and palpation by an endocrinologist.13 A blood 
sample was collected in order to determine thyroid hormone levels and antithyroid 
antibodies.13 Iodine excretion was estimated after collection of a spot urine sample.13 A 
structured interview was also performed inquiring about demographic and medical 
characteristics, residential history, and consumption of milk during May and June of 
1986.13 After screening, subjects could be referred to a clinic in Kyiv to receive fine 
needle aspiration biopsy (FNAB) for nodules larger than 10 mm or for nodules 5-10 mm 
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that were at least partly solid and had indirect signs of malignancy.13 Anyone directly 
involved in the screening process was unaware of individual dose estimates.13  
 Previous power calculations had determined that about 12,000 people would be 
needed for the study based on a log-normal dose distribution model.13 There were 32,385 
individuals with individual measurements of radioactivity originally chosen for the study 
(≤ 18 years old at the time of the accident) from the database of all radioactivity 
measurements made in Ukraine.13 Based on preliminary dose estimates, the selected 
individuals included everyone in the highest dose group (≥ 1 Gy) and a sample of people 
with doses less than 1 Gy.13 Members of the lower dose group were chosen in an attempt 
to provide risk estimates with a comparable degree of precision relative to the high dose 
group.13 Potential participants were contacted either in person or by telephone, and the 
study was advertised in newspapers and on radio broadcasts during initial recruitment.13 
Of 32,385 individuals, 10,307 (31.8%) could not be traced, largely because of changes in 
residential location during the long time period between the accident and the start of 
screening.4 In addition, 2,466 (7.6%) were traced but were ineligible or unavailable to 
participate, and 6,369 (19.7%) were traced but either refused participation or did not 
attend the screening.4  
Follow-up screening of the cohort was planned to occur every two years. 
Newsletters and post cards were sent to cohort members regularly to remind them of their 
involvement in the study.13 For those who could not be contacted during a given 
screening cycle, tracing was attempted through family members and friends in an effort 
to minimize losses to follow-up.13 The final cohort for the present study included 13,243 
individuals, and the cohort considered for data analysis was 13,008 individuals after 
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exclusions. Exclusion criteria included ages less than zero (exposed in utero) or greater 
than 18 years old on April 26, 1986, absence of thyroid dose estimate, oblast (province) 
of residence other than Zhytomyr, Kyiv, or Chernihiv, previous diagnosis of thyroid 
cancer, previous thyroid surgery or thyroid aplasia, self-reported history of thyroid 
hormone intake, or missing information on ultrasound examination.5,48  
Dosimetry 
 Details of the dosimetric methods have been described elsewhere.13,39,49 Briefly, 
individual thyroid radioactivity measurements were obtained for each member of the 
cohort.49 The main components of exposure to the thyroid after the Chernobyl accident 
were internal irradiation from ingestion of I-131, internal irradiation from intake of short 
lived radioiodines such as I-132, I-133, and I-135 as well as short lived radiotellurium 
such as Te-131m and Te-132, external irradiation from radionuclides deposited on the 
ground such as Cs-137 and Cs-134, and internal irradiation from ingestion of long-lived 
radionuclides.2 I-131 is estimated to have on average provided about 95% of the total 
thyroid dose based on studies in Belarus.54,55 I-131 primarily contributed to thyroid dose 
through the consumption of contaminated milk and leafy green vegetables. This generally 
resulted in higher thyroid doses for young children relative to adults.10,49 Internal 
exposure to I-131 lasted for a few weeks after the accident due to its physical half-life of 
approximately 8.04 days.49 Most direct thyroid radioactivity measurements were made 
after shorter-lived isotopes such as I-133 (half-life: 21 hours) and Tellerium-132 (half-
life: 3.2 days) had largely decayed away but before I-131 had decayed considerably.5  
 Members of the cohort received a wide range of dose estimates from 0.000348 Gy 
to 41.56 Gy with a mean of 0.64 Gy. Thyroid doses from I-131 were calculated through 
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1,000 Monte Carlo realizations based on radioactivity measurements, interview data 
regarding residential history and dietary habits two months following the accident, and 
radioecological models of I-131 transport in the environment and biokinetic models of I-
131 in the body.49 In the analyses, we used the arithmetic mean of the 1,000 realizations 
per individual of improved I-131 thyroid dose estimates. Geometric standard deviations 
of the 1,000 realizations, a measure of uncertainty in estimates of individual I-131 thyroid 
doses, were approximated log-normally distributed and ranged between 1.26 and 10.6, 
with an arithmetic mean of 1.55 and a geometric mean of 1.47.39 These are generally 
smaller than uncertainties reported in other studies of environmental I-131 exposure.39 
Statistical Analysis 
 The outcomes of interest were defined as (1) the presence of at least one thyroid 
nodule detected on ultrasound examination regardless of any specific characteristics 
(n=263) and (2) the presence of at least one non-neoplastic nodule (after excluding those 
who were confirmed to have thyroid cancer or follicular adenoma following thyroid 
surgery, n=219). To estimate an excess odds ratio for thyroid nodule prevalence (EOR = 
OR - 1) and to compute likelihood-based 95% confidence intervals (95% CI), we used 
binary logistic regression that seeks to find a coefficient value minimizing the sum of 
squared deviance residuals.  
The linear EOR model has the following form: Odds(x, d) = p(x, d)/[1 - p(x, d)] = 
r(x)*[1 +  f(d)], where x is vector of covariates, d is I-131 thyroid dose, r(x) is function of 
background parameters when d=0, and f(d) is a function describing the effect of I-131. In 
this linear-exponential model, excess risk due to radiation multiplies the background 
parameters including gender, oblast of residence, age at examination, and thyroid 
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volume, with age and volume modelled parametrically. When evaluating either the main 
effect of I-131 dose or background factors, these are included in the model 
simultaneously.5,48 If a strictly linear dose-response is assumed, f(d) = β*d and β is an 
estimated parameter that measures the unit increase in EOR per Gy.4 Departure from 
linearity in dose-response can be tested by fitting a linear-exponential model f(d) = 
β*d*exp–γ*d or a linear-quadratic model f(d) = β*d + γ*d2. To evaluate effect modification 
of the dose-response, f(d) is allowed to vary by the category of a given factor under 
investigation. The respective likelihood ratio test is based on a comparison of nested 
models, one with the main effects of radiation and the factor of interest, and the other 
including an additional product term of the factor with dose. 
Both attained age (age at screening) and age at exposure were tested as effect 
modifiers. However, because they are correlated, it is difficult to separate their 
independent effects.5 In contrast, only attained age was used to characterize the 
background risk since it is biologically meaningful regardless of radiation exposure.5 
Other variables that were considered as effect modifiers included the following: place of 
residency (urban or rural), oblast of residence (Zhytomyr, Kyiv, or Chernihiv) both at the 
time of screening and in 1986, smoking status (yes or no), serum concentration of thyroid 
stimulating hormone (TSH), thyroglobulin (Tg), and level of antibody to thyroid 
peroxidase (ATPO), urinary iodine concentration, and thyroid volume. All statistical tests 
were two-sided with a specified type I error of 0.05. Estimation of the parameters was 
based on likelihood methods using the GMBO module of the EPICURE package.56 All 
analyses were conducted for each thyroid nodule outcome. 
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To examine the effect of I-131 dose on thyroid nodule size (≥10 mm or <10 mm), 
we also conducted analyses using polytomous logistic regression. The choice of a 10 mm 
cutoff point was clinically motivated since thyroid microcarcinoma is defined by a size 
less than 10 mm.51 Furthermore, palpation has been shown to be less reliable at detecting 























Background Risk Factors 
Among 13,008 members of the cohort included in the analysis, there were a total 
of 263 individuals with at least one thyroid nodule detected at ultrasound examination 
(2.02%), including 57 that proved to be thyroid carcinoma or adenoma following thyroid 
surgery. Selected associations with the background risk of prevalent thyroid nodules 
using the best fitting dose-response model under consideration (linear-exponential over 
the entire dose range with adjustment for sex, oblast of residence, age at screening, 
thyroid volume, and I-131 thyroid dose and effect modification by oblast of residence) 
are presented in Table 1. Associations between background risk factors and prevalent 
thyroid nodules using a simple logistic regression model without considering dose are 
presented in Appendix A. There were no meaningful differences in risk estimates or their 
pattern in analyses based on all prevalent nodules and nodules excluding thyroid 
carcinoma and adenoma. Females had a greater background risk of thyroid nodule 
prevalence than males. The background risk increased with increasing age at screening, 
leveling off at older ages. This was best described by a linear quadratic function. The 
background risk of having thyroid nodules was also higher for those living in the 
Chernihiv oblast or Kyiv oblast compared with those living in the Zhytomyr oblast. 








Table 1: Associations between background risk factors and thyroid nodules using the 
best fitting dose-response model. 
 
 
Cases Noncases Entire Cohort 
 






N N % OR (95% CI) P-Value a OR (95% CI) P-Value a 
Sex * 








Female 196 6375 3.07 3.67 (2.77, 4.94) 
 
3.61 (2.65, 4.99) 
 
        









16 to 19 44 2987 1.47 2.02 (1.17, 3.63) 
 
2.02 (1.10, 3.92) 
 
20 to 22 59 2279 2.59 3.85 (2.62, 6.88) 
 
3.84 (2.12, 7.40) 
 
23 to 25 51 2384 2.14 3.10 (1.79, 5.61) 
 
2.86 (1.54, 5.60) 
 
> 25 91 2834 3.21 4.84 (2.89, 8.54) 
 
4.73 (2.65, 8.99) 
 
        









Kyiv 57 2759 2.07 1.40 (0.74, 2.68) 
 
1.34 (0.75, 2.34) 
 
Chernihiv 146 6554 2.23 1.23 (0.75, 2.23) 
 
1.11 (0.70, 1.83) 
 
        
Type of Residence * 








Urban 73 3678 1.98 0.95 (0.71, 1.26) 
 
0.95 (0.69, 1.29) 
 
        
Smoking Status * 








Current Smoker 59 4124 1.43 0.93 (0.65, 1.31) 
 
1.06 (0.73, 1.53) 
 
        









Yes 41 1257 3.26 1.32 (0.91, 1.88) 
 
1.45 (0.97, 2.11) 
 
Unknown 49 3004 1.63 
    
        









8.0 to < 10.0 34 2895 1.17 1.32 (0.78, 2.27) 
 
1.60 (0.89, 2.99) 
 
10.0 to < 14.0 79 3842 2.06 2.50 (1.59, 4.06) 
 
2.98 (1.78, 5.29) 
 
14.0 to 90.5 126 2999 4.20 5.32 (3.43, 8.58) 
 




Table 1 Continued 
        









30.0 to < 50.0 59 3418 1.73 0.85 (0.57, 1.23) 
 
0.76 (0.71, 1.13) 
 
50.0 to < 70.0 41 2178 1.88 0.98 (0.57, 1.46) 
 
0.87 (0.48, 1.34) 
 
70.0 to 1820.5 64 2778 2.30 1.07 (0.69, 1.54) 
 
1.07 (0.69, 1.57) 
 
Unknown 33 1218 2.71 
    
* The best fitting model was linear-exponential over the whole dose range and included adjustment for sex, 
   oblast of residence, age at screening, thyroid volume, and I-131 thyroid dose and effect modification by oblast. 
a All p-values were based on likelihood ratio tests of nested models.                                     
^ Numbers may not add up to column total because of missing values (excluded from analyses).  
 
Type of residence, self-reported history of smoking, and urinary iodine 
concentration were not significantly associated with thyroid nodule prevalence. Having 
reported at least one relative with a history of thyroid disease was associated with a 
higher background prevalence of thyroid nodules, although approximately 24% of 
individuals had no such data available and after adjustment for thyroid volume, this 
association was no longer significant. Serum levels of TSH and ATPO were not 
associated with background prevalence of thyroid nodules (see Appendix B), while 
higher levels of Tg were significantly associated with higher background prevalence. 
Because serum levels of TSH, ATPO, and Tg might be affected by the presence of 
thyroid nodules and because their inclusion had no meaningful influence on estimates of 
I-131’s effects, these variables were not retained in the final models. 
Dose-response with I-131 
After adjusting for background risk factors, there was strong evidence of a dose-
response for prevalence of thyroid nodules based on categorical analyses of I-131 dose 
(see Table 2). This was true in the analyses based on all nodules and nodules excluding 
thyroid carcinoma and adenoma. However, I-131 risk estimates in the analyses based on 
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non-neoplastic nodules tended to be lower, particularly at high doses. Next, simple linear 
EOR models were fitted, and significant linear trends were found with an EOR of 0.89 
(95% CI: 0.42, 1.64) and 0.41 (95% CI: 0.09, 0.95) for prevalence of all nodules and 
prevalence of non-neoplastic nodules, respectively. Evaluating departure from the simple 
linear EOR model for each outcome, we found that linear-exponential (p-value: 0.00460 
and p-value: 0.0182), but not linear quadratic (p-value: > 0.50 and p-value: > 0.50) 
models described the data significantly better than simple linear models over the entire 
range of doses. Figure 2 shows categorical estimates of odds ratios and fitted linear and 
linear-exponential dose-responses over the whole dose range for prevalence of all 
nodules. According to the best fitting linear-exponential model, the I-131 risk at high 
doses (> 5 Gy) goes down, potentially suggesting a cell killing effect. The dose-response 
for prevalence of non-neoplastic nodules was not as steep (not shown), although the 
overall pattern was similar. 









Benign Neoplasms  
Dose (Gy) N N % OR (95% CI) OR (95% CI) 
< 0.1* 75 4330 1.73 1.00 (Referent) 1.00 (Referent) 
0.1 to <0.25* 61 2929 2.08 1.57 (1.10, 2.23) 1.56 (1.08, 2.26) 
0.25 to <0.5* 40 2007 1.99 1.67 (1.10, 2.50) 1.38 (0.87, 2.16) 
0.5 to <1.0* 37 1573 2.35 2.47 (1.50, 3.75) 2.14 (1.33, 3.37) 
1.0 to <2.0* 23 1051 2.19 2.53 (1.51, 4.14) 1.96 (1.07, 3.40) 
2.0 to <5.0* 22 629 3.50 4.44 (2.53, 7.51) 2.59 (1.29, 4.86) 
5.0 to 41.56* 5 226 2.21 4.62 (1.55, 11.18) 2.68 (0.63, 7.74) 
* All odds ratios were adjusted for sex, oblast of residence, age at screening, and thyroid volume.  
* P-value for trend was < 0.001 for all nodules and < 0.001 for non-neoplastic nodules.  
 
When the analyses were limited to those receiving doses less than 5 Gy, the 
inclusion of an exponential term for dose no longer significantly improved the model’s fit 
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either for prevalence of all nodules or prevalence of non-neoplastic nodules (p-value: > 
0.50 and p-value: > 0.50) and data were consistent with linearity. Figure 3 shows 
categorical estimates of odds ratios and fitted linear and linear-exponential dose-
responses < 5 Gy for prevalence of all nodules; the respective plots for prevalence of 
non-neoplastic nodules are not shown. The EORs < 5 Gy for prevalence of all nodules 
and prevalence of non-neoplastic nodules were 1.08 (95% CI: 0.53, 1.95) and 0.57 (95% 
CI: 0.17, 1.22), respectively. 
 
 
Figure 2: Relationship between dose and odds ratios over the whole dose range using 
models with linear, linear-exponential, and categorical dose. The dashed and solid lines 
represent fitted odds ratios based on linear and linear-exponential EOR models, 
respectively, over the entire dose range. Data points and error bars represent category-
specific odds ratios and 95% confidence intervals for the mean I-131 dose per category. 
The fitted dose-responses were adjusted to pass through the lowest I-131 category. The 






Figure 3: Relationship between dose and odds ratios under 5 gray using models with 
linear, linear-exponential, and categorical dose. The dashed and solid lines represent 
fitted odds ratios based on linear and linear-exponential EOR models, respectively, under 
5 gray. Data points and error bars represent category-specific odds ratios and 95% 
confidence intervals for the mean I-131 dose per category. The fitted dose-responses 
were adjusted to pass through the lowest I-131 category. The EOR was adjusted for sex, 
oblast of residence, thyroid volume, and age at screening. 
 
Modification of I-131 Dose-response Under 5 Gray 
 
Effect modification of the EORs by selected characteristics < 5 Gy is shown in 
Table 3. We found significant effect modification of the EOR/Gy by oblast of residence, 
with higher EORs estimated for the Chernihiv oblast than for the Kyiv or Zhytomyr 
oblasts. This was true for both prevalence of all thyroid nodules and prevalence of non-
neoplastic nodules (see Figures 4 and 5). No significant modification of the EOR/Gy by 
sex, age at exposure or screening, type of residence, thyroid volume, or urinary iodine 
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concentration for either outcome was found. The EORs per Gy for categories of serum 
TSH, ATPO, and Tg are presented in Appendix C. 
Table 3: Effect modification of the excess odds ratio of prevalent thyroid nodules per 





Excluding Thyroid Cancer / 
Benign Neoplasms 
 






Male  0.74 (0.12, 2.08) 
 
0.51 (-0.03, 1.81) 
 
Female 1.34 (0.62, 2.55) 
 
0.63 (0.15, 1.48) 
 
     





< 16 0.51 (-0.26, 2.87) 
 
0.09 (-0.32, 1.47) 
 
16 to 19 1.09 (0.33, 2.54) 
 
0.49 (-0.04, 1.58) 
 
20 to 22 1.92 (0.64, 4.13) 
 
1.18 (0.15, 3.11) 
 
23 to 25 0.97 (0.19, 2.32) 
 
0.49 (-0.06, 1.59) 
 
> 25 1.21 (0.33, 2.79) 
 
0.89 (0.13, 2.32) 
 
     





0 to 4 0.95 (0.14, 3.00) 
 
0.39 (-0.10, 1.79) 
 
4 to 8 1.38 (0.44, 3.06) 
 
0.76 (0.03, 2.12) 
 
8 to 10 1.38 (0.29, 3.33) 
 
0.63 (-0.12, 2.22) 
 
10 to 14 0.77 (0.16, 1.82) 
 
0.37 (-0.05, 1.19) 
 
14 to 18 1.97 (0.51, 4.83) 
 
1.77 (0.35, 4.65) 
 
     





Zhytomyr 0.36 (-0.01, 1.21) 
 
0.04 (-0.16, 0.55) 
 
Kyiv 0.51 (-0.12, 2.05) 
 
0.14 (-0.30, 1.28) 
 
Chernihiv 2.31 (1.12, 4.32) 
 
1.77 (0.74, 3.60) 
 
     





Rural 1.44 (0.72, 2.54) 
 
0.82 (0.28, 1.71) 
 
Urban 0.58 (0.02, 1.52) 
 
0.20 (-0.19, 0.95) 
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< 8.0 0.49 (-0.05, 1.51) 
 
0.00 (-0.37, 0.76) 
 
8.0 to <10.0 0.57 (-0.03, 1.68) 
 
0.22 (-0.27, 1.15) 
 
10.0 to <14.0 1.46 (0.61, 2.82) 
 
0.75 (0.16, 1.82) 
 
14.0 to 90.5 2.46 (1.31, 4.71) 
 
1.78 (0.65, 3.73) 
 
     
Urinary Iodine (µg/L) * ^  > 0.50  > 0.50 
< 30.0 1.36 (0.52, 2.76)  0.96 (0.26, 2.19)  
30.0 to <50.0 0.87 (0.16, 2.10)  0.27 (-0.17, 1.19)  
50.0 to <70.0 2.13 (0.87, 4.16)  1.34 (0.31, 3.08)  
70.0 to 1820.5 1.22 (0.73, 2.69)  0.83 (0.06, 2.16)  
* EOR/Gy was adjusted for sex, oblast of residence, age at screening, thyroid volume, and I-131 dose.  
a All p-values were based on likelihood ratio tests of nested models. 
  





Figure 4: Relationship between dose and odds ratios under 5 gray including effect 






Figure 5: Relationship between dose and odds ratios under 5 gray with effect 
modification by oblast excluding nodules that proved to be neoplastic. 
 
Based on polytomous regression analyses of small (< 10 mm, n=54) and large (≥ 
10 mm, n=209) nodules in the dose range < 5 Gy, the EOR/Gy for those with large 
nodules was 0.92 (95% CI: 0.41, 1.74) and for those with small nodules was 1.80 (95% 
CI: 0.47, 5.30). However, these slopes were not significantly different based on a 
likelihood ratio test (p-value: 0.306). Similarly, the slopes were also not significantly 
different (p-value: 0.438) when nodules that proved to be thyroid cancer or follicular 
adenoma were excluded, with an EOR/Gy of 0.49 (95% CI: 0.10, 1.14) for those with 










In this study of a cohort of children and adolescents exposed to radioactive I-131 
after the Chernobyl accident, there was a strong association between thyroid dose 
received from I-131 and prevalence of at least one thyroid nodule. Over the entire range 
of doses, there was evidence for departure from linearity due to a statistically significant 
exponential relationship between dose and risk, with decreasing risk at higher doses. 
Biologically, the decline in risk at higher doses may represent cell sterilization due to cell 
killing or limited ability of the affected cells to reproduce. Instead of becoming 
cancerous, cells receiving high doses may be killed or rendered unable to reproduce. 
When analyses were restricted to I-131 doses below 5 Gy, the dose-response was 
consistent with linearity. 
After excluding those with thyroid nodules that proved to be thyroid cancer or 
follicular adenoma, the magnitude of the dose-response was reduced but the overall shape 
was similar to that over the whole dose range. This observation suggests that I-131 
exposure is more effective in inducing thyroid cancer or follicular adenoma than non-
neoplastic thyroid nodules and, therefore, the fraction of I-131 attributable cases of 
thyroid cancer in this population is higher than the fraction of I-131 attributable non-
neoplastic thyroid nodules. It is also possible that thyroid nodule formation may occur at 
lower I-131 doses on average than thyroid carcinogenesis. However, the dose-response 
for thyroid nodules could change with further follow-up of the cohort as time since 
exposure increases. The lower magnitude of the linear part of the I-131 dose-response for 
non-neoplastic thyroid nodules compared with that for all nodules is not particularly 
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surprising since previous analyses in the Ukrainian-American cohort found an ERR/Gy 
of 2.07 for follicular adenoma, which is a benign neoplasm, while the ERR/Gy for 
prevalent thyroid cancer was 5.25.5,48 Estimated risks in the current study are also 
somewhat lower than but compatible with risks for all nodules (EOR/Gy: 1.65) and 
benign nodules (EOR/Gy: 2.07) in atomic bomb survivors under the age of 10 at the time 
of exposure.98  
Previous literature has been contradictory regarding risk of thyroid cancer based 
on nodule size. Some studies have found that larger nodules were associated with a 
higher risk of thyroid cancer than smaller nodules while others have not.8,62,74 Size alone 
appears to be of limited use for diagnostic purposes.23 However, when considered with 
other thyroid nodule characteristics, size may help to improve sensitivity and specificity. 
Indeed, guidelines have been suggested for ultrasound detection of thyroid nodules 
involving nodule size that reduced the false positive rate and increased the positive 
likelihood ratio.72 By requiring at least 2 of 3 thyroid nodule characteristics – presence of 
microcalcifications, a size greater than 2 cm, and an entirely solid composition – the 
number of biopsies per thyroid cancer diagnosed was reduced.72 Data from this study 
suggest that the linear dose-response may be greater for small nodules (< 10 mm) than 
large nodules (≥ 10 mm) even when thyroid cancer and adenoma were excluded.  
However, while the estimates of EOR/Gy for small nodules were twice the estimates for 
large nodules, there were only 54 individuals with nodules < 10 mm and the differences 
were not significant. Some have proposed that thyroid nodules start as benign or 
malignant from the beginning of their development rather than undergo malignant 
transformation at a later point.101 It remains unclear whether radiation exposure might be 
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an initiating event in thyroid nodule development, a promoting event, or both. One study 
has suggested that radiation exposure may contribute more to nodule growth rather than 
to initial nodule formation.98 While a seemingly greater risk for smaller nodules with 
increasing dose is not consistent with such a hypothesis, there is also not strong evidence 
against it in the present study due to uncertainty in risk estimates.  
 The data concerning an interaction between sex and dose received have been 
inconsistent. Some but not all studies of thyroid cancer found that females had larger 
ERRs/Gy than males, but this relationship has been observed less frequently for thyroid 
nodules.12,42,53,58,91 Although the EOR/Gy was slightly lower for males in the current 
study, the interaction was not significant. Several studies of external radiation and I-131 
found that the younger a person at the time of exposure, the greater the risk of developing 
radiation-induced thyroid cancer and thyroid nodules at some point in the 
future.7,12,42,53,58,91 This implies that the thyroid is more sensitive to radiation in children 
and adolescents than in adults. While the underlying biological mechanisms of these 
differences remain unknown, variations in thyroid metabolism are likely to be important 
contributors.63 Consistent with the age at exposure effect, Belarus, Ukraine, and four 
regions in Russia saw the highest increases in thyroid cancer incidence among those 
exposed as children or adolescents.10 In the present study, there was no consistent pattern 
in the EORs/Gy across age at exposure categories, and likelihood ratio tests for the 
interaction were not significant. This is similar to the study of follicular thyroid adenoma 
(a benign thyroid neoplasm) in the same cohort.48 However, previous studies of thyroid 
cancer in the Ukrainian-American cohort found that those exposed at older ages had a 
lower ERR/Gy than those exposed at younger ages, although the difference was not 
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statistically significant.4,5 Overall, age at exposure and sex did not significantly modify 
the relationship between I-131 dose and thyroid nodule prevalence in the current study of 
all thyroid nodules and of non-neoplastic nodules. 
Iodine deficiency has been considered a potential modifier of radiation-related 
thyroid cancer risk since it results in reduced levels of thyroid hormone production, a 
subsequent increase in TSH production, and increased stimulation of thyroid cell 
proliferation.44 Previous research found that self-reported intake of stable iodine was 
associated with lower risk of I-131 related thyroid cancer while residence within iodine-
deficient territories at the time of the accident was associated with higher risk.45 Iodine 
status can be difficult to accurately measure, and not all studies have found iodine 
deficiency to be a risk factor.4  
In general, the modifying role of iodine deficiency is challenging to study because 
measures of stable iodine intake at an individual level during the most relevant time 
period, the time at exposure, are rarely available in retrospective epidemiological studies. 
In the present study, iodine intake indicators were measured 12-14 years after the 
accident and therefore may not reflect iodine status at the time of the accident. 
Collectively, these indicators suggest that at the time of first screening, the study 
population was mildly-to-moderately iodine deficient. However, there is evidence that 
iodine intake has been increasing since the late 1990s across Ukraine due to changes in 
diet and iodine supplementation, which may further alter the usefulness of measured 
urinary iodine concentration as a proxy indicator for iodine status in 1986.45 Furthermore, 
serum biomarkers have been shown to possess limited sensitivity and specificity in 
differentiating various types of thyroid diseases.70,74 
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Since thyroid volume may be a marker of past iodine deficiency and does not 
change as quickly as urinary iodine or serum Tg, it was preferred for inclusion in dose-
response models over urinary iodine concentration and other measured serum 
biomarkers.86,88 Although only crude measurements were available for thyroid volume, it 
may be a reasonable proxy indicator for iodine status at the time of the accident, 
particularly if iodine intake did not drastically change during the period between 
exposure and initial screening. Even so, the thyroid volume measurements used in the 
present study are limited since they were taken from a cross-section of the cohort years 
after the accident occurred. In the current study, individuals with larger thyroid volumes 
had a somewhat higher EOR/Gy, but the difference was not statistically significant. I-131 
related risks also tended to be higher among individuals with higher levels of serum Tg. 
An interaction between dose and urinary iodine concentration was not significant, and 
there was no clear pattern of change in EOR/Gy across categories of urinary iodine 
concentration, serum ATPO levels, or TSH levels. Based on available indicators of iodine 
intake, the data do not provide strong support for a modifying effect of iodine deficiency 
on I-131 related risk of thyroid nodules. 
The significant interaction between I-131 dose and oblast of residence has been 
suggested in previous studies.4,53 Since cohort screening was conducted according to a 
standardized protocol and no significant differences were observed in compliance rates 
with FNAB or thyroid surgery by oblast, case ascertainment was unlikely to have caused 
a geographic difference. The three oblasts are relatively similar in socioeconomic level 
and ethnicity, but oblast may be a surrogate indicator for some unmeasured effect 
modifier. Previous studies of various thyroid diseases such as thyroid cancer, follicular 
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adenoma, hypothyroidism, and autoimmune-related outcomes have also found or 
suggested an interaction between oblast of residence and I-131 dose.4,89,92,93 
After the Chernobyl accident, those living within the 30 km zone were relocated 
to other areas of Ukraine, most often within the same oblast.45 Since few people changed 
oblast of residence between 1986 and 1998 (362, or 2.8%), oblast may be a useful proxy 
indicator for iodine status around the time of the Chernobyl accident. In addition, type of 
residency (urban or rural) may have contributed to local differences in intake of stable 
iodine. The Kyiv oblast contained more cohort participants living in urban areas at the 
time of the accident (47.1%), while Zhytomyr (16.2%) and Chernihiv (28.7%) contained 
fewer. At the time of the accident, residents of large cities such as Kyiv mainly relied on 
food imported from other regions of Ukraine or the Soviet Union that may have come 
from territories rich in soil iodine.45 Smaller towns and rural areas, however, consumed a 
diet that was composed more heavily of food grown in the local, iodine-poor soils.45 
People living in many areas of Ukraine still remain iodine deficient according to recent 
literature.87 Even people living in the more urban Kyiv region are mildly iodine deficient 
on average.85 
The background risk for thyroid nodules in the current study was higher for 
females and older individuals. In the general population, rates of thyroid cancer are three 
to four times higher in females as in males under the age of 50 years, and incidence 
increases with age as people are generally assumed to spontaneously develop thyroid 
nodules as they get older.2 Risk was also increased for those with larger thyroid volumes. 
This seems reasonable since average thyroid volume likely increases with the presence of 
thyroid nodules. Urinary iodine concentration was not significantly associated with 
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thyroid nodule prevalence. Urinary iodine concentration and various serum biomarkers 
for iodine deficiency have been suggested as biologically meaningful indicators of 
thyroid disease risk in the past.2,43,44,45,86 Furthermore, previous studies in Ukraine and 
Belarus found that a higher thyroid cancer risk was associated with presence of diffuse 
goiter, a marker of past iodine deficiency.5,6 Depending on other physiological conditions, 
diffuse goiter can be associated with elevated serum Tg levels and lower serum TSH 
levels, particularly in those without sufficient iodine intake; however, this is not always 
the case.50,88 Based on available indicators of iodine intake in the present study, the data 
do not provide strong support for an effect of iodine deficiency on thyroid nodule risk. 
 Caution should be used in comparing the results of this study to other situations 
involving exposure to radioiodines since differences in the types of exposure and 
composition of the radioactive nuclides may affect both the doses received and patterns 
of risk observed. This makes direct comparisons of risks in the current study and studies 
of populations previously living near the Hanford nuclear site or the Mayak nuclear 
facility, as well as those exposed to fallout in Kazakhstan, Nevada, and the Marshall 
Islands, challenging. Studying risk of thyroid diseases related to radioactive fallout is 
complicated due to difficulties in reconstructing radiation doses and uncertainties in dose 
estimates. Studies of environmental exposure to radioactive iodines that do not have 
individual thyroid radioactivity measurements available, such as those involving the 
Hanford nuclear site, rely on retrospective dose reconstructions based on residential 
history collected years after the exposures occurred.16 Additionally, the duration and 
temporal pattern of exposures following the Chernobyl nuclear accident and Hanford 
plant operation differed since exposures near the Hanford site lasted over a period of 
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years. Because I-131’s physical half-life is 8.04 days and I-131 was released into the 
environment over a period of 10 days following the Chernobyl accident, the I-131 
released into the environment had largely decayed within the first two months after the 
accident. 
Variations in certain characteristics, such as age at exposure or iodine sufficiency, 
can also modify the underlying susceptibility of a given population to the development of 
radiation-related thyroid nodules and therefore affect the observed risks. Furthermore, 
exposure to radioisotopes other than I-131 may alter the types of doses received. Studies 
of people exposed to radioactive fallout may have involved exposures to substantial 
levels of gamma radiation that may carry different risks.2,13,38 A study of those exposed to 
radioactive fallout in Kazakhstan found a significant positive relationship between 
internal radiation exposure, which was mainly from I-131, and prevalence of thyroid 
nodules.30 Internal exposure to iodine radionuclides was estimated to be about 1/4 to 
1/3 as 
effective as exposure to external radiation at inducing thyroid nodules.30 However, more 
recent research using Bayesian methods to take uncertainties into account found that 
biological effectiveness was similar for internal and external radiation dose in the 
cohort.84 Studies of the cohort in Ukraine suggest that exposure to I-131 has about the 
same risk for thyroid cancer as acute, external exposures do.2 However, whether the same 
is true for  thyroid nodules remains unclear. 
 Strengths of the study include the use of individual I-131 dose estimates that were 
calculated from radioactivity measurements taken within two months after the accident, a 
standardized uniform screening examination, and a high rate of compliance with FNAB 
(75%) and surgery (80%).4 An international pathology review that provided independent 
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confirmation of thyroid cancer and follicular adenoma diagnosis, which should provide a 
high degree of diagnostic accuracy for neoplastic thyroid disease.13 Although only 44% 
of those contacted became a part of the cohort, the distributions of measured thyroid 
radioactivity were similar for participants and nonparticipants.5 Since the radioactivity 
measurements were similar between participants and nonparticipants, potential non-
differential bias (if present) may therefore attenuate the odds ratio estimate for the effect 
of I-131. Participant and nonparticipant distributions were also similar by gender but 
differed by type of residence since some residents from urban areas were more mobile.48 
The proportion of participants who were older at the time of the accident was smaller 
since they were more likely to have moved away in the intervening years.48 To minimize 
the effect of bias and to model the background prevalence, all dose-response analyses 
were adjusted for gender, age, and oblast of residence. The estimated odds ratio is a 
reasonable approximation of risk when the prevalence of an outcome, such as thyroid 
nodules, is low and when thyroid nodules identified by screening progress to a clinically 
detectable state.5,48 A commonly used criteria for calculating the odds ratio as an 
approximation of the relative risk is a prevalence below 10%, although this boundary is 
somewhat arbitrary.15 The prevalence of thyroid nodules in the current study, 2.02%, falls 
well below the threshold.  
Due to the lack of individual data on iodine nutrition in 1986, thyroid volume and 
urinary iodine concentration measured during the first screening cycle (12-14 years after 
the accident) were used in our analyses.13 Another potential limitation is that the impact 
of uncertainties in dose estimates was not taken into account. Most of the uncertainty in 
doses came from variability in thyroid mass and radioactivity measurements.49 The 
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presence of both classical and Berkson measurement error with shared and unshared 
errors in dose estimates can lead to bias of the odds ratio either toward or away from the 
null.5 Dose errors in the Ukrainian-American cohort are relatively minor. Formal 
analyses of radiation risk of thyroid cancer taking into account uncertainty in doses did 
not find a meaningful difference between unadjusted and adjusted EORs. Adjustments to 
the EOR from regression calibration methods ranged from an 7% increase to an 11% 
decrease, while a Monte Carlo maximum likelihood technique taking into account a 
mixture of Berkson and classical errors in dose resulted in an 8% decrease in EOR.14 This 
may be due in part to the fact that errors associated with thyroid mass are largely 


















The results of the present study show a positive, linear-exponential relationship 
between I-131 dose thyroid dose and risk of thyroid nodule prevalence. This strongly 
suggests that I-131 from the Chernobyl accident is related to an increase in thyroid 
nodule risk among those exposed as children or adolescents. The excess radiation risk for 
thyroid nodules detected at the time of first screening was smaller than for thyroid cancer, 
but additional follow-up of the cohort is necessary to describe the excess radiation risks 
over time.  
Future studies of radiation-related thyroid cancer and thyroid nodules may benefit 
from considering genetic biomarkers. While results of studies involving somatic 
mutations, epigenetics, and proteomic and immunohistochemical biomarkers are still 
preliminary, they could provide valuable information for differentiating benign thyroid 
nodules and thyroid cancer. Further validation of biomarkers in terms of their ability to 
distinguish between benign nodules and various types of thyroid cancer should continue. 
Studies of RET/PTC and PAX8/PPARγ rearrangements and BRAF and RAS point 
mutations have already been performed in the Ukrainian-American cohort.81 Important 
information has been gathered on the relationship between biomarkers and thyroid 
cancer, but the natural history of thyroid nodules and thyroid cancer is still not fully 
understood. Further follow-up of the existing cohorts, as well as large scale tissue-based 
studies, are necessary to improve comprehension of genetic and environmental roles in 
thyroid cancer formation. The collection of plausible biomarkers, combined with the 
strengths of a longitudinal cohort having a wide range of doses and standardized 
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screening, could increase our understanding of the biological development of thyroid 
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ASSOCIATIONS BETWEEN BACKGROUND RISK FACTORS AND THYROID 







Excluding Thyroid Cancer / 
 
(N=263) (N=12745) 
   
Benign Neoplasms 
 
N N % OR (95% CI) P-Value a OR (95% CI) P-Value a 
Sex * 








Female 196 6375 3.07 2.96 (2.25, 3.94) 
 
2.94 (2.18, 4.02) 
 
        









16 to 19 44 2987 1.47 1.83 (1.07, 3.25) 
 
1.91 (1.05, 3.67) 
 
20 to 22 59 2279 2.59 3.31 (1.99, 5.79) 
 
3.59 (2.03, 6.77) 
 
23 to 25 51 2384 2.14 2.71 (1.61, 4.78) 
 
2.79 (1.55, 5.32) 
 
> 25 91 2834 3.21 4.18 (2.57, 7.18) 
 
4.58 (2.67, 8.48) 
 
        
Oblast of Residence * 








Kyiv 57 2759 2.07 1.05 (0.72, 1.52) 
 
1.34 (0.87, 2.07) 
 
Chernihiv 146 6554 2.23 1.27 (0.94, 1.72) 
 
1.76 (1.21, 2.63) 
 
        
Type of Residence * 








Urban 73 3678 1.98 0.86 (0.65, 1.14) 
 
0.86 (0.63, 1.16) 
 
        
Smoking Status * 








Current Smoker 59 4124 1.43 0.91 (0.64, 1.27) 
 
1.02 (0.71, 1.46) 
 
        
Relatives Affected * ^ 








Yes 41 1257 3.26 1.54 (1.07, 2.17) 
 
1.64 (1.11, 2.38) 
 
Unknown 49 3004 1.63 
    
        
Thyroid Volume (mL) * 








8.0 to <10.0 34 2895 1.17 1.39 (0.83, 2.39) 
 
1.68 (0.93, 3.13) 
 
10.0 to <14.0 79 3842 2.06 2.69 (1.71, 4.36) 
 
3.17 (1.89, 5.61) 
 
14.0 to 90.5 126 2999 4.20 5.86 (3.80, 9.42) 
 




Appendix A Continued 
       
Urinary Iodine (μg/L) * ^ 








30.0 to <50.0 59 3418 1.73 0.81 (0.57, 1.15) 
 
0.72 (0.50, 1.07) 
 
50.0 to <70.0 41 2178 1.88 0.88 (0.83, 1.30) 
 
0.78 (0.48, 1.21) 
 
70.0 to 1820.5 64 2778 2.30 1.02 (0.69, 1.45) 
 
1.04 (0.69, 1.51) 
 
Unknown 33 1218 2.71 
    
       
Serum ATPO (U/mL) * ^ 








4.0 to <17.0 77 3059 2.52 1.43 (0.63, 2.04) 
 
1.42 (0.96, 2.12) 
 
17.0 to <35.0 61 3181 1.92 1.10 (0.10, 1.60) 
 
1.24 (0.83, 1.87) 
 
35.0 to 18066.0 66 3256 2.03 1.15 (0.14, 1.66) 
 
1.21 (0.81, 1.82) 
 
Unknown 5 125 4.00 
    
        









8.5 to <16.0 44 3005 1.46 1.05 (0.00, 1.61) 
 
1.22 (0.29, 1.96) 
 
16.0 to <30.0 63 3068 2.05 1.45 (0.65, 2.18) 
 
1.56 (0.79, 2.46) 
 
30.0 to 643.0 104 2893 3.59 2.48 (0.91, 3.63) 
 
2.61 (0.96, 4.01) 
 
Unknown 11 859 1.28 
    
        
Serum TSH (mIU/L) * ^ 








1.26 to <1.80 65 2824 2.30 0.93 (0.66, 1.29) 
 
0.78 (0.54, 1.13) 
 
1.80 to <2.70 69 3635 1.90 0.78 (0.56, 1.07) 
 
0.70 (0.49, 0.99) 
 
2.70 to 50.0 43 2907 1.48 0.62 (0.42, 0.89) 
 
0.55 (0.36, 0.83) 
 
Unknown 5 123 4.07 
    
* All odds ratios were adjusted for sex, oblast of residence, and age at screening. 
  
a All p-values were based on likelihood ratio tests of nested models.                                     
 
















ASSOCIATIONS BETWEEN BACKGROUND RISK FACTORS AND THYROID 
NODULES FOR SELECTED BIOMARKERS USING THE BEST 
FITTING DOSE-RESPONSE MODEL 
 
 
Cases Noncases Entire Cohort 
 






N N % OR (95% CI) P-Value a OR (95% CI) P-Value a 









4.0 to < 17.0 77 3059 2.52 1.52 (0.76, 2.19) 
 
1.51 (0.74, 2.27) 
 
17.0 to < 35.0 61 3181 1.92 1.18 (0.24, 1.72) 
 
1.33 (0.48, 2.01) 
 
35.0 to 18066.0 66 3256 2.03 1.05 (0.05, 1.53) 
 
1.12 (0.12, 1.70) 
 
Unknown 5 125 4.00 
    
        
Serum Thyroglobulin (ng/mL) * ^ < 0.001 
 
0.00293 




8.5 to < 16.0 44 3005 1.46 1.05 (0.01, 1.63) 
 
1.21 (0.28, 1.95) 
 
16.0 to < 30.0 63 3068 2.05 1.31 (0.45, 1.97) 
 
1.37 (0.53, 2.17) 
 
30.0 to 643.0 104 2893 3.59 1.92 (1.65, 2.83) 
 
1.98 (0.68, 3.07) 
 
Unknown 11 859 1.28 
    
        









1.26 to < 1.80 65 2824 2.30 01.01 (0.72, 1.41) 
 
0.85 (0.59, 1.23) 
 
1.80 to < 2.70 69 3635 1.90 0.83 (0.59, 1.15) 
 
0.74 (0.52, 1.06) 
 
2.70 to 50.0 43 2907 1.48 0.64 (0.44, 0.94) 
 
0.58 (0.38, 0.88) 
 
Unknown 5 123 4.07 
    
* The best fitting model was linear-exponential over the whole dose range and included adjustment for sex, 
   oblast of residence, age at screening, thyroid volume, and I-131 thyroid dose and effect modification by oblast. 
a All p-values were based on likelihood ratio tests of nested models.                                     














EFFECT MODIFICATION OF THE EXCESS ODDS RATIO OF PREVALENT 






Excluding Thyroid Cancer / 
Benign Neoplasms 
 
EOR Per Gy (95% CI) P-Value a EOR Per Gy (95% CI) P-Value a 





< 4.0 1.06 (0.30, 2.30) 
 
0.28 (-0.25, 1.26) 
 
4.0 to <17.0 1.91 (0.91, 3.72) 
 
0.98 (0.20, 2.39) 
 
17.0 to <35.0 1.29 (0.40, 2.77) 
 
0.86 (0.14, 2.13) 
 
35.0 to 18066.0 1.05 (0.34, 2.21) 
 
0.68 (0.11, 1.64) 
 
     
Serum Thyroglobulin (ng/mL) * ^  < 0.001 
 
0.0949 
< 8.5 1.03 (0.35, 2.18) 
 
0.48 (-0.02, 1.38) 
 
8.5 to <16.0 0.75 (0.04, 2.00) 
 
0.45 (-0.14, 1.59) 
 
16.0 to <30.0 1.42 (0.45, 2.99) 
 
0.89 (0.11, 2.22) 
 
30.0 to 643.0 2.12 (0.94, 4.01) 
 
1.10 (0.28, 2.52) 
 
     





< 1.26 1.17 (0.40, 2.48) 
 
1.03 (0.28, 2.30) 
 
1.26 to <1.80 1.83 (0.76, 3.53) 
 
1.17 (0.30, 2.61) 
 
1.80 to <2.70 1.34 (0.52, 2.62) 
 
0.72 (0.04, 1.85) 
 
2.70 to 50.0 0.46 (-0.05, 0.60) 
 
0.15 (-0.25, 0.90) 
 
* EOR/Gy was adjusted for sex, oblast of residence, age at screening, thyroid volume, and I-131 dose. 
 
a All p-values were based on likelihood ratio tests of nested models. 
  
^ Interactions were not included in the final model due to missing values (excluded from analyses).  
 
 
